Hsbc Holdings PLC Has $1.71 Million Position in Abivax SA Sponsored ADR $ABVX

Hsbc Holdings PLC boosted its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 335.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,426 shares of the company’s stock after purchasing an additional 11,887 shares during the quarter. Hsbc Holdings PLC’s holdings in Abivax were worth $1,712,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after acquiring an additional 2,595 shares during the period. Millennium Management LLC raised its holdings in Abivax by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after acquiring an additional 56,235 shares during the period. Woodline Partners LP lifted its position in Abivax by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after acquiring an additional 153,788 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Abivax during the 2nd quarter worth $139,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ABVX shares. Wolfe Research set a $136.00 price target on Abivax in a research report on Wednesday, June 3rd. Piper Sandler increased their target price on Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $187.00 target price on shares of Abivax in a report on Wednesday, July 1st. Leerink Partners lifted their price target on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $180.00 price target on shares of Abivax in a report on Friday. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Abivax currently has a consensus rating of “Moderate Buy” and an average price target of $156.50.

Abivax Price Performance

Abivax stock opened at $125.70 on Monday. The business has a 50 day moving average price of $117.99 and a two-hundred day moving average price of $118.22. The stock has a market cap of $10.97 billion, a price-to-earnings ratio of -24.13 and a beta of 0.87. Abivax SA Sponsored ADR has a 12 month low of $65.67 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, analysts expect that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.